Why Johnson & Johnson Stock Dropped Today
Johnson & Johnson (JNJ) shares fell 6.8% despite beating Q3 earnings estimates and raising 2026 guidance. Adjusted EPS was $2.59 on $25.4B sales, but GAAP EPS dropped 96% YoY due to one-time charges. The company expects 7.4% sales growth and $11.10 adjusted EPS for 2026.
How this was made
The 30-second read
Why it matters
The immediate trading reaction is driven by the mismatch between adjusted strength and GAAP deterioration, plus valuation concerns raised by the author.
Market read
Provides same-day, company-specific earnings and guidance details that explain why the stock sold off despite an adjusted beat.
What to watch
The article cites specific drivers of the GAAP decline (talc litigation resolution proposal, Firefly Bio acquisition, Sail Biomedicines collaboration), so traders may want to separate recurring operating trends from one-time accounting effects before extrapolating a fundamental deterioration.
Background
The piece frames JNJ’s Q3 as an adjusted earnings beat with raised 2026 guidance, but highlights a sharp GAAP earnings collapse tied to special charges.
Ticker impact
Johnson & Johnson shares fell 6.8% after Q3 results showed a GAAP profit plunge and a one-time charge, despite adjusted EPS beat and raised 2026 guidance.
Likely continued downside or choppy trading as investors weigh raised sales and adjusted EPS against the magnitude of GAAP deterioration and the implied earnings quality.
The article attributes the same-day selloff to the GAAP profit collapse and special charges, while noting adjusted EPS beat and higher guidance, which sets up a near-term debate on whether the guidance offsets the earnings quality hit.
Market effects
Reinforces that investors may punish pharma/healthcare earnings quality when GAAP is hit by litigation-related charges, even if adjusted metrics beat.
Primarily single-name impact on US large-cap healthcare sentiment.
Limited spillover beyond healthcare peers that face similar litigation or accounting charge dynamics.
Counterpoint
The guidance raise and strong free cash flow growth suggest the GAAP drop may be largely non-recurring, so the selloff could be overdone if investors focus on cash generation and adjusted earnings power.
Key entities
- companyJohnson & Johnson
US-listed healthcare company reporting Q3 results, free cash flow, and raised 2026 guidance; stock dropped on GAAP earnings decline and special charges.
